Mereo BioPharma Group PLC ADR (MREO)

  • Get an in-depth profile of Mereo BioPharma Group PLC ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
1.330 -0.020 (-1.48%)
Close USD Disclaimer
1.320 -0.010 (-0.752%)

Mereo BioPharma Group PLC ADR Company Profile

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
36
Equity Type
ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
Contact Information
Address
London,W1G 0QF United Kingdom
Phone
44 33 3023 7300
Fax
-
Web
https://www.mereobiopharma.com
Top Executives
Name
Age
Since
Title
Michael Stephen Wyzga 68 2020 Independent Non-Executive Chairman of The Board
Deepika Rachel Pakianathan 58 2019 Independent Non-Executive Director
Anders Ekblom 69 2015 Independent Non-Executive Director
Marc J. Yoskowitz 48 2022 Independent Director
Denise Scots-Knight 64 2015 Co-Founder, CEO & Executive Director
Pierre Jacquet 55 2021 Independent Director
Jeremy Bender 51 2020 Independent Non Executive Director
Daniel A. Shames 77 2022 Independent Director
Justin Roberts 40 2022 Independent Director

Customize

Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Related Articles